

PATH, SD Biosensor partner to advance malaria treatment

21 June 2018 | News

PATH is advancing a portfolio of novel rapid tests for G6PD deficiency that are low cost, simple to use, and meet specifications to improve treatment of patients with *P. vivax* malaria and support elimination programs.



PATH has announced a new partnership with South Korean company SD BIOSENSOR to support the development and availability in key markets of a new diagnostic intended to support malaria elimination efforts. PATH and SD BIOSENSOR developed the Standard G6PD Test to guide appropriate clinical care of patients with *Plasmodium vivax* malaria who also have a hereditary enzyme deficiency that can lead to severe anemia if the patient receives treatment with 8-aminoquinoline-based drugs to cure the infection.

PATH is advancing a portfolio of novel rapid tests for G6PD deficiency that are low cost, simple to use, and meet specifications to improve treatment of patients with *P. vivax* malaria and support elimination programs. As part of this work, PATH partnered with SD BIOSENSOR to develop and evaluate a new diagnostic for G6PD deficiency.

PATH will support and guide SD BIOSENSOR in the registration, manufacture, and sale of the new test in countries where *P. vivax* is endemic and this product will be most impactful. PATH will work with SD BIOSENSOR to provide the STANDARD G6PD Test at favorable pricing terms to priority countries, ensuring that cost will not pose a significant barrier to access where the test is needed most.